THE APEX TIMES
CVS Health schedules Aug. 5 call for second-quarter 2026 results
The company will discuss its second-quarter financial performance with analysts and investors on Wednesday, August 5 at 8:00 a.m. ET, with a live webcast and a replay archived for one year.
CVS Health will hold its second-quarter 2026 earnings conference call on Wednesday, August 5, 2026, at 8:00 a.m. ET, according to a notice distributed in advance of the results release. Management plans to discuss the company’s second-quarter financial results with analysts and investors during the call.
CVS said an audio webcast of the event will be broadcast simultaneously on its Investor Relations website. The recording will be archived there for a period of one year, giving investors an option to review the discussion after the live session.
The announcement was posted by major financial news aggregators after appearing through a press-release distribution channel. In the same material, CVS described its integrated health model and the scale of its operations, including approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics, as of March 31, 2026.
CVS also reiterated that its pharmacy benefits management (PBM) business serves about 88 million plan members, and that it reaches an estimated more than 37 million people through health insurance products and related services. PBM is the part of the business that manages prescription drug benefits on behalf of insurers and employers, and it is a major lever for costs and access across the U.S. drug supply chain.
For investors, the August call sets a marker for how CVS will explain performance across its retail pharmacy and clinic network, its PBM activity, and its insurance-related services. Earnings calls are typically where management updates quarterly trends in utilization, margins, and operating costs, and addresses developments that can affect demand for prescriptions, patient visits, and insurance enrollment.
The company did not specify in the announcement itself what particular topics it expects to emphasize during the call, nor did it provide any preliminary financial guidance, targets, or business milestones. As a result, the market will likely wait until the quarter’s earnings materials and prepared remarks to determine what is driving results.
CVS’s next-quarter narrative may also hinge on how the company manages the operational complexities of integrating services that span pharmacies, primary care and insurance-related offerings. In a sector where reimbursement, drug pricing and benefit design can shift quickly, investors commonly use earnings calls to judge the stability of underlying demand and the durability of margins.
Why It Matters
- The August 5 call gives investors a scheduled checkpoint for how CVS’ retail, PBM, and insurance-related businesses performed in the second quarter.
- Because CVS’ scale spans multiple parts of healthcare delivery and benefits, quarterly results can influence expectations for cost trends and margins across the broader healthcare services sector.
- The webcast replay availability suggests the company expects ongoing investor interest beyond the live session, which often matters for how quickly market participants digest new guidance and commentary.
Sources
Key Facts
- CVS Health will hold its second-quarter 2026 earnings conference call on Wednesday, August 5, 2026 at 8:00 a.m. ET.
- The company plans to discuss second-quarter 2026 financial results with analysts and investors during the call.
- CVS said an audio webcast will be available on its Investor Relations site, with a replay archived for one year.
- CVS reported it had approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics as of March 31, 2026.
- CVS said its PBM business has approximately 88 million plan members.
- CVS said it serves an estimated more than 37 million people through health insurance products and related services.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.